Also, GLP-1 delays gastric emptying ( 5 ), increases satiety, suppresses food intake, and reduces weight in humans ( 6, 7 )
Disproportionality analysis A sequential approach was adopted to systematically address major confounders: (1) An exploratory disproportionality approach comparing GLP-1RAs with all other drugs reported in the FAERS database, using venlafaxine as the positive control and empagliflozin/orlistat as the negative control
In a phase 2 dose-finding trial in adults with obesity or overweight, survodutide produced dose-dependent reductions in body weight and was described as a glucagon receptorGLP-1 receptor dual agonist
AstraZeneca previously licensed a GLP-1 small molecule from Eccogene, aiming for GLP-1 + amylin combo therapy
Animal models Based on established literature [32], the UC mouse model was induced in this study by providing free access to drinking water containing 3% dextran sulfate sodium (DSS, MP Biomedicals, USA) for 7 days (Fig
We introduce recent studies that demonstrate the remarkable performance of GLP-1RAs in slowing the progression of neurodegenerative diseases, reducing inflammation, and enhancing cardiovascular health